STAROPOLI, Nicoletta
 Distribuzione geografica
Continente #
NA - Nord America 435
EU - Europa 339
AS - Asia 259
SA - Sud America 65
AF - Africa 4
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.105
Nazione #
US - Stati Uniti d'America 414
IT - Italia 174
SG - Singapore 153
DE - Germania 69
BR - Brasile 56
CN - Cina 53
GB - Regno Unito 23
FI - Finlandia 20
CA - Canada 17
SE - Svezia 12
VN - Vietnam 12
HK - Hong Kong 11
RU - Federazione Russa 11
NL - Olanda 9
IN - India 8
TR - Turchia 7
ES - Italia 5
CZ - Repubblica Ceca 4
AR - Argentina 3
AT - Austria 3
BD - Bangladesh 3
FR - Francia 3
ID - Indonesia 3
JP - Giappone 3
MX - Messico 3
PL - Polonia 3
ZA - Sudafrica 3
CL - Cile 2
PK - Pakistan 2
UA - Ucraina 2
VE - Venezuela 2
AU - Australia 1
CO - Colombia 1
EC - Ecuador 1
EU - Europa 1
IQ - Iraq 1
JO - Giordania 1
KI - Kiribati 1
LB - Libano 1
PT - Portogallo 1
TL - Timor Orientale 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 1.105
Città #
Singapore 84
Dallas 61
Munich 58
Chandler 44
Hefei 34
Ashburn 26
Santa Clara 25
Chicago 23
Turku 19
London 17
Milan 17
Carbonia 12
Catanzaro 12
Hong Kong 11
Naples 11
Rome 11
Lawrence 10
Princeton 10
Los Angeles 8
New York 8
The Dalles 8
Wilmington 8
Boardman 7
Ottawa 7
Parma 7
São Paulo 6
Montreal 5
Beijing 4
Charlotte 4
Ercolano 4
Hanoi 4
Melito di Porto Salvo 4
Olomouc 4
Reggio Calabria 4
Afragola 3
Amsterdam 3
Ankara 3
Atlanta 3
Ho Chi Minh City 3
Moscow 3
Nuremberg 3
Redmond 3
Santo Stefano di Rogliano 3
Tokyo 3
Warsaw 3
Augusta 2
Benevento 2
Bisignano 2
Bismarck 2
Boston 2
Brooklyn 2
Buffalo 2
Campina Grande 2
Catania 2
Cavallino 2
Chennai 2
Columbus 2
Des Moines 2
Esslingen am Neckar 2
Gatchina 2
Jiaxing 2
Johannesburg 2
Lahore 2
Manaus 2
Manchester 2
Marcianise 2
Mountain View 2
Niterói 2
Osasco 2
Phoenix 2
Pittsburgh 2
Rio de Janeiro 2
Romainville 2
San Nicola Manfredi 2
Seattle 2
Serra San Bruno 2
Shenzhen 2
Spezzano della Sila 2
St Petersburg 2
Stockholm 2
Washington 2
West Lafayette 2
Acri 1
Alvorada 1
Amman 1
Aracaju 1
Araguari 1
Balıkesir 1
Bay City 1
Beirut 1
Bengaluru 1
Berlin 1
Boituva 1
Bologna 1
Bắc Giang 1
Caicó 1
Campina Verde 1
Campinas 1
Canberra 1
Cape Town 1
Totale 702
Nome #
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 89
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 60
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 54
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 51
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 51
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 50
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 48
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 48
Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report 46
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 43
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 43
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 42
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 42
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 39
Economic Evaluation Of A New Non-Antibiotic First-line Treatment Of Recurrent Urinary Tract Infections 39
Personalized medicine in colorectal cancer diagnosis and treatment: a systematic review of health economic evaluations 36
Ramucirumab In Gastric Cancer Treatment: An Economic Evaluation 35
Cardiotoxicity of anti-HER2 drugs in the treatment of metastatic breast cancer: Case report 31
Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity 28
Prevalence of Non-Erosive Esophageal Phenotypes in children: a European multicenter study 27
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience 24
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma 24
Modeling UGT2B7 and NR1I3 genes through multilayer network to highlight hidden link with taxane neurotoxicity 23
LNA-i-miR-221 activity in colorectal cancer: A reverse translational investigation 23
Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) 22
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 22
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis 21
First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis 21
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma 19
Bioinformatic challenges for pharmacogenomic study: tools for genomic data analysis 16
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis 13
Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program 13
Why Do You Treat pCR Patient With Pertuzumab and Trastuzumab? 11
Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper 4
Totale 1.158
Categoria #
all - tutte 10.613
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.613


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202124 0 0 0 2 3 3 1 0 5 9 1 0
2021/202244 0 0 1 17 0 2 0 8 4 8 2 2
2022/2023171 22 9 5 8 14 13 4 7 25 28 31 5
2023/2024135 41 10 12 6 7 25 1 1 0 7 13 12
2024/2025487 31 13 8 7 20 77 15 19 42 8 104 143
2025/2026285 74 112 99 0 0 0 0 0 0 0 0 0
Totale 1.158